Gemfibrozil treatment of hypertriglyceridemia: Improvement on fibrinolysis without change of insulin resistance
The fibrinolytic and metabolic changes associated with gemfibrozil treatment of hypertriglyceridemia were evaluated in 16 patients with type IV hyperlipidemia by criteria of triglyceride levels >250 mg/dl and total cholesterol levels
Gespeichert in:
| Veröffentlicht in: | The American heart journal 1997-09, Vol.134 (3), p.565-571 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 571 |
|---|---|
| container_issue | 3 |
| container_start_page | 565 |
| container_title | The American heart journal |
| container_volume | 134 |
| creator | Jeng, Jing-Ren Jeng, Chii-Yuan Sheu, Wayne Huey-Herng Lee, May Meei-Shyuan Huang, Shyuh-Huei Shieh, Shyh-Ming |
| description | The fibrinolytic and metabolic changes associated with gemfibrozil treatment of hypertriglyceridemia were evaluated in 16 patients with type IV hyperlipidemia by criteria of triglyceride levels >250 mg/dl and total cholesterol levels |
| doi_str_mv | 10.1016/S0002-8703(97)70096-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79309456</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870397700966</els_id><sourcerecordid>79309456</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-d3d266a71206978116d3f63a3b462e0e9549f58aa3e18c7f2b0239dae98bce763</originalsourceid><addsrcrecordid>eNqFkF1r2zAUhsXoaNNuPyHgi1LWC6_6cCRrN2WULisUetHtWsjycXKGbWWSnJH--tpJyO2uhDjPez4eQuaMfmWUybtXSinPS0XFF61uFaVa5vIDmTGqVS5VUZyR2Qm5IJcx_hm_kpfynJxrwZViakb8EroGq-DfsM1SAJs66FPmm2y920BIAVftzkHAGjq037KnbhP8Fg5Qn01R7H27ixizf5jWfkiZW9t-BVMP7OPQYp8FGOvJ9g4-kY-NbSN8Pr5X5PePx18PP_Pnl-XTw_fn3IlSp7wWNZfSKsap1KpkTNaikcKKqpAcKOhFoZtFaa0AVjrV8IpyoWsLuqwcKCmuyM2h77ju3wFiMh1GB21re_BDNEoLqovFBC4OoAs-xgCN2QTsbNgZRs0k2uxFm8mi0crsRZspNz8OGKoO6lPqaHasXx_rNjrbNmG8HuMJ4-U4e4_dHzAYZWwRgokOYRRVYwCXTO3xP4u8A6sEnK4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79309456</pqid></control><display><type>article</type><title>Gemfibrozil treatment of hypertriglyceridemia: Improvement on fibrinolysis without change of insulin resistance</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Jeng, Jing-Ren ; Jeng, Chii-Yuan ; Sheu, Wayne Huey-Herng ; Lee, May Meei-Shyuan ; Huang, Shyuh-Huei ; Shieh, Shyh-Ming</creator><creatorcontrib>Jeng, Jing-Ren ; Jeng, Chii-Yuan ; Sheu, Wayne Huey-Herng ; Lee, May Meei-Shyuan ; Huang, Shyuh-Huei ; Shieh, Shyh-Ming</creatorcontrib><description>The fibrinolytic and metabolic changes associated with gemfibrozil treatment of hypertriglyceridemia were evaluated in 16 patients with type IV hyperlipidemia by criteria of triglyceride levels >250 mg/dl and total cholesterol levels <220 mg/dl. The plasma triglyceride level was significantly lower (323 ± 71 vs 189 ± 57 mg/dl;
p = 0.000) and high-density lipoprotein cholesterol level significantly higher (33.5 ± 4.6 vs 38.0 ± 6.7 mg/dl;
p = 0.005) after 3 to 4 months of gemfibrozil treatment. However, the glucose and insulin metabolism measured by oral glucose challenge and insulin suppression tests showed no significant changes after gemfibrozil therapy. In contrast, plasma plasminogen activator inhibitor-1 antigen (36.9 ± 12.4 vs 27.3 ± 11.4 ng/ml;
p = 0.008) and activity (15.5 ± 5.5 vs 11.8 ± 3.0 IU/ml;
p = 0.009) and tissue plasminogen activator antigen (13.2 ± 4.0 vs 10.4 ± 3.7 ng/ml;
p = 0.007) were significantly depressed, and tissue plasimogen activator activity (0.57 ± 0.31 vs 0.69 ± 0.38 IU/ml;
p = 0.015) was significantly elevated by gemfibrozil. The data indicate that lowering plasma triglyceride and raising high-density lipoprotein cholesterol levels by gemfibrozil treatment also improved the fibrinolytic system without changes of insulin resistance and glucose intolerance in patients with isolated hypertriglyceridemia. (Am Heart J 1997;134:565-71.)</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/S0002-8703(97)70096-6</identifier><identifier>PMID: 9327717</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Cholesterol, HDL - blood ; Female ; Fibrinolysis - drug effects ; Gemfibrozil - pharmacology ; Gemfibrozil - therapeutic use ; General and cellular metabolism. Vitamins ; Humans ; Hypertriglyceridemia - blood ; Hypertriglyceridemia - drug therapy ; Hypertriglyceridemia - physiopathology ; Hypolipidemic Agents - pharmacology ; Hypolipidemic Agents - therapeutic use ; Insulin Resistance ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Triglycerides - blood</subject><ispartof>The American heart journal, 1997-09, Vol.134 (3), p.565-571</ispartof><rights>1997 Mosby, Inc.</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-d3d266a71206978116d3f63a3b462e0e9549f58aa3e18c7f2b0239dae98bce763</citedby><cites>FETCH-LOGICAL-c389t-d3d266a71206978116d3f63a3b462e0e9549f58aa3e18c7f2b0239dae98bce763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0002-8703(97)70096-6$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2856317$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9327717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jeng, Jing-Ren</creatorcontrib><creatorcontrib>Jeng, Chii-Yuan</creatorcontrib><creatorcontrib>Sheu, Wayne Huey-Herng</creatorcontrib><creatorcontrib>Lee, May Meei-Shyuan</creatorcontrib><creatorcontrib>Huang, Shyuh-Huei</creatorcontrib><creatorcontrib>Shieh, Shyh-Ming</creatorcontrib><title>Gemfibrozil treatment of hypertriglyceridemia: Improvement on fibrinolysis without change of insulin resistance</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>The fibrinolytic and metabolic changes associated with gemfibrozil treatment of hypertriglyceridemia were evaluated in 16 patients with type IV hyperlipidemia by criteria of triglyceride levels >250 mg/dl and total cholesterol levels <220 mg/dl. The plasma triglyceride level was significantly lower (323 ± 71 vs 189 ± 57 mg/dl;
p = 0.000) and high-density lipoprotein cholesterol level significantly higher (33.5 ± 4.6 vs 38.0 ± 6.7 mg/dl;
p = 0.005) after 3 to 4 months of gemfibrozil treatment. However, the glucose and insulin metabolism measured by oral glucose challenge and insulin suppression tests showed no significant changes after gemfibrozil therapy. In contrast, plasma plasminogen activator inhibitor-1 antigen (36.9 ± 12.4 vs 27.3 ± 11.4 ng/ml;
p = 0.008) and activity (15.5 ± 5.5 vs 11.8 ± 3.0 IU/ml;
p = 0.009) and tissue plasminogen activator antigen (13.2 ± 4.0 vs 10.4 ± 3.7 ng/ml;
p = 0.007) were significantly depressed, and tissue plasimogen activator activity (0.57 ± 0.31 vs 0.69 ± 0.38 IU/ml;
p = 0.015) was significantly elevated by gemfibrozil. The data indicate that lowering plasma triglyceride and raising high-density lipoprotein cholesterol levels by gemfibrozil treatment also improved the fibrinolytic system without changes of insulin resistance and glucose intolerance in patients with isolated hypertriglyceridemia. (Am Heart J 1997;134:565-71.)</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cholesterol, HDL - blood</subject><subject>Female</subject><subject>Fibrinolysis - drug effects</subject><subject>Gemfibrozil - pharmacology</subject><subject>Gemfibrozil - therapeutic use</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Hypertriglyceridemia - blood</subject><subject>Hypertriglyceridemia - drug therapy</subject><subject>Hypertriglyceridemia - physiopathology</subject><subject>Hypolipidemic Agents - pharmacology</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Insulin Resistance</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Triglycerides - blood</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkF1r2zAUhsXoaNNuPyHgi1LWC6_6cCRrN2WULisUetHtWsjycXKGbWWSnJH--tpJyO2uhDjPez4eQuaMfmWUybtXSinPS0XFF61uFaVa5vIDmTGqVS5VUZyR2Qm5IJcx_hm_kpfynJxrwZViakb8EroGq-DfsM1SAJs66FPmm2y920BIAVftzkHAGjq037KnbhP8Fg5Qn01R7H27ixizf5jWfkiZW9t-BVMP7OPQYp8FGOvJ9g4-kY-NbSN8Pr5X5PePx18PP_Pnl-XTw_fn3IlSp7wWNZfSKsap1KpkTNaikcKKqpAcKOhFoZtFaa0AVjrV8IpyoWsLuqwcKCmuyM2h77ju3wFiMh1GB21re_BDNEoLqovFBC4OoAs-xgCN2QTsbNgZRs0k2uxFm8mi0crsRZspNz8OGKoO6lPqaHasXx_rNjrbNmG8HuMJ4-U4e4_dHzAYZWwRgokOYRRVYwCXTO3xP4u8A6sEnK4</recordid><startdate>19970901</startdate><enddate>19970901</enddate><creator>Jeng, Jing-Ren</creator><creator>Jeng, Chii-Yuan</creator><creator>Sheu, Wayne Huey-Herng</creator><creator>Lee, May Meei-Shyuan</creator><creator>Huang, Shyuh-Huei</creator><creator>Shieh, Shyh-Ming</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970901</creationdate><title>Gemfibrozil treatment of hypertriglyceridemia: Improvement on fibrinolysis without change of insulin resistance</title><author>Jeng, Jing-Ren ; Jeng, Chii-Yuan ; Sheu, Wayne Huey-Herng ; Lee, May Meei-Shyuan ; Huang, Shyuh-Huei ; Shieh, Shyh-Ming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-d3d266a71206978116d3f63a3b462e0e9549f58aa3e18c7f2b0239dae98bce763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cholesterol, HDL - blood</topic><topic>Female</topic><topic>Fibrinolysis - drug effects</topic><topic>Gemfibrozil - pharmacology</topic><topic>Gemfibrozil - therapeutic use</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Hypertriglyceridemia - blood</topic><topic>Hypertriglyceridemia - drug therapy</topic><topic>Hypertriglyceridemia - physiopathology</topic><topic>Hypolipidemic Agents - pharmacology</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Insulin Resistance</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Triglycerides - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jeng, Jing-Ren</creatorcontrib><creatorcontrib>Jeng, Chii-Yuan</creatorcontrib><creatorcontrib>Sheu, Wayne Huey-Herng</creatorcontrib><creatorcontrib>Lee, May Meei-Shyuan</creatorcontrib><creatorcontrib>Huang, Shyuh-Huei</creatorcontrib><creatorcontrib>Shieh, Shyh-Ming</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jeng, Jing-Ren</au><au>Jeng, Chii-Yuan</au><au>Sheu, Wayne Huey-Herng</au><au>Lee, May Meei-Shyuan</au><au>Huang, Shyuh-Huei</au><au>Shieh, Shyh-Ming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gemfibrozil treatment of hypertriglyceridemia: Improvement on fibrinolysis without change of insulin resistance</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>1997-09-01</date><risdate>1997</risdate><volume>134</volume><issue>3</issue><spage>565</spage><epage>571</epage><pages>565-571</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>The fibrinolytic and metabolic changes associated with gemfibrozil treatment of hypertriglyceridemia were evaluated in 16 patients with type IV hyperlipidemia by criteria of triglyceride levels >250 mg/dl and total cholesterol levels <220 mg/dl. The plasma triglyceride level was significantly lower (323 ± 71 vs 189 ± 57 mg/dl;
p = 0.000) and high-density lipoprotein cholesterol level significantly higher (33.5 ± 4.6 vs 38.0 ± 6.7 mg/dl;
p = 0.005) after 3 to 4 months of gemfibrozil treatment. However, the glucose and insulin metabolism measured by oral glucose challenge and insulin suppression tests showed no significant changes after gemfibrozil therapy. In contrast, plasma plasminogen activator inhibitor-1 antigen (36.9 ± 12.4 vs 27.3 ± 11.4 ng/ml;
p = 0.008) and activity (15.5 ± 5.5 vs 11.8 ± 3.0 IU/ml;
p = 0.009) and tissue plasminogen activator antigen (13.2 ± 4.0 vs 10.4 ± 3.7 ng/ml;
p = 0.007) were significantly depressed, and tissue plasimogen activator activity (0.57 ± 0.31 vs 0.69 ± 0.38 IU/ml;
p = 0.015) was significantly elevated by gemfibrozil. The data indicate that lowering plasma triglyceride and raising high-density lipoprotein cholesterol levels by gemfibrozil treatment also improved the fibrinolytic system without changes of insulin resistance and glucose intolerance in patients with isolated hypertriglyceridemia. (Am Heart J 1997;134:565-71.)</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>9327717</pmid><doi>10.1016/S0002-8703(97)70096-6</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-8703 |
| ispartof | The American heart journal, 1997-09, Vol.134 (3), p.565-571 |
| issn | 0002-8703 1097-6744 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79309456 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Biological and medical sciences Cholesterol, HDL - blood Female Fibrinolysis - drug effects Gemfibrozil - pharmacology Gemfibrozil - therapeutic use General and cellular metabolism. Vitamins Humans Hypertriglyceridemia - blood Hypertriglyceridemia - drug therapy Hypertriglyceridemia - physiopathology Hypolipidemic Agents - pharmacology Hypolipidemic Agents - therapeutic use Insulin Resistance Male Medical sciences Middle Aged Pharmacology. Drug treatments Triglycerides - blood |
| title | Gemfibrozil treatment of hypertriglyceridemia: Improvement on fibrinolysis without change of insulin resistance |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T08%3A45%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gemfibrozil%20treatment%20of%20hypertriglyceridemia:%20Improvement%20on%20fibrinolysis%20without%20change%20of%20insulin%20resistance&rft.jtitle=The%20American%20heart%20journal&rft.au=Jeng,%20Jing-Ren&rft.date=1997-09-01&rft.volume=134&rft.issue=3&rft.spage=565&rft.epage=571&rft.pages=565-571&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/S0002-8703(97)70096-6&rft_dat=%3Cproquest_cross%3E79309456%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79309456&rft_id=info:pmid/9327717&rft_els_id=S0002870397700966&rfr_iscdi=true |